Compare COO & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | HOLX |
|---|---|---|
| Founded | 1980 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 16.6B |
| IPO Year | N/A | 1990 |
| Metric | COO | HOLX |
|---|---|---|
| Price | $81.36 | $74.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | ★ $85.82 | $79.64 |
| AVG Volume (30 Days) | ★ 3.3M | 3.0M |
| Earning Date | 12-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.87 | ★ 2.49 |
| Revenue | $4,092,400,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $6.66 | $6.69 |
| Revenue Next Year | $5.54 | $5.74 |
| P/E Ratio | $43.53 | ★ $30.11 |
| Revenue Growth | ★ 5.06 | 1.74 |
| 52 Week Low | $61.78 | $51.90 |
| 52 Week High | $104.47 | $80.31 |
| Indicator | COO | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 72.89 | 67.93 |
| Support Level | $75.25 | $74.55 |
| Resistance Level | $78.69 | $75.12 |
| Average True Range (ATR) | 2.48 | 0.28 |
| MACD | 0.47 | -0.14 |
| Stochastic Oscillator | 55.39 | 78.92 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.